晚期软组织肉瘤的治疗:机遇与挑战
王臻
空军军医大学附属西京医院骨科, 710032 西安
摘要：Soft tissue sarcomas (STS) are a group of rare and highly heterogeneous neoplasms with mesenchymal origin.The main management for STS is surgical resection but with a high rate of recurrence and metastasis.The first-line chemotherapy for advanced STS is doxorubicin or combination with ifosfamide.Now, molecular targeted therapy becomes a new approach for STS.Anlotinib, a novel tyrosine kinase inhibitor, showed antitumor activity in several STS entities.But for advanced progressive STS, targeted therapy need to combine with local intervention, such as argon-helium cryosurgery, local radiotherapy, interventional embolization, et al.Patients should have cytoreductive surgery if they have operation indication.The initial outcomes of clinical trials of immunotherapy also showed a satisfactory efficacy in STS.Despite the advances in the above therapies, novel therapeutics are needed.We should continuously explore and improve the multidisciplinary therapy of STS.
关键词：晚期软组织肉瘤治疗
分类号：R738.6(运动系肿瘤)
论文发表日期：2019-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 1-2 )
英文信息